Trial Profile

Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-61393215 as Adjunctive Treatment in Adults With Major Depressive Disorder With Anxious Distress With Suboptimal Response to Standard Antidepressants

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JNJ 61393215 (Primary)
Indications Anxiety disorders; Attention-deficit hyperactivity disorder; Major depressive disorder; Post-traumatic stress disorders
Focus Proof of concept; Therapeutic Use
Sponsors Janssen Research & Development

11 Nov 2021 Status changed from recruiting to completed.
27 May 2021 Planned End Date changed from 8 Oct 2021 to 6 Oct 2021.
27 May 2021 Planned primary completion date changed from 24 May 2021 to 6 Oct 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com